Novo Nordisk doubles obesity sales in 2022
Although supply issues have plagued Novo Nordisk’s Obesity Care in large portions of 2022, the Danish drugmaker has still managed to break records at the end of fiscal 2022 for the rapidly growing business unit, revealed the annual report on Wednesday.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Novo Nordisk predicts wide range for 2023 sales growth
For subscribers
Analyst: Wegovy prescriptions continue upward trend in US
For subscribers